Longeveron was founded on the premise that the very cells within our bodies whose primary function is to repair, restore and regenerate damaged tissue and organs may be developed into a safe and effective “off-the-shelf” cell therapy to treat chronic aging-related diseases and other life-threatening conditions, to improve healthspan, and to extend longevity.

Since our founding in 2014, we have focused our efforts on generating clinical safety and efficacy data in our selected indications, building, staffing and equipping a state-of-the art GMP manufacturing and research and development facility, expanding our intellectual property portfolio, developing and expanding our manufacturing processes and capabilities.

Our programs have been awarded more than $16.2 million in grant funding from the 
National Institute on Aging (NIA) of the National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI) of NIH, the Alzheimer’s Association, and the Maryland Stem Cell Research Fund (MSCRF) of the Maryland TEDCO.


We manufacture our own product candidates for clinical research and product development in our GMP facility, comprised of eight clean rooms, two research and development laboratories, and warehouse and storage space. We have supply contracts with multiple third parties for fresh bone marrow, which we use to produce our lead therapeutic candidate called Lomecel-B™. From time to time we enter into contract development and manufacturing contracts or arrangements with third parties who seek to utilize our product development capabilities.

Our therapeutic indications currently under clinical study are:

• Hypoplastic Left Heart Syndrome

• Alzheimer’s Disease

• Aging Frailty

• Metabolic Syndrome
• Acute Respiratory Distress Syndrome due to COVID-19 or Influenza